Is split‐dose better than single‐dose? Results of Turkish Stem Cell Coordination Center (<scp>TURKOK</scp>) donors in the era of rising biosimilar <scp>G‐CSF</scp>

Pınar, İbrahim Ethem; Özkocaman, Vildan; Özkalemkaş, Fahir; Durgut, Himmet; Dakiki, Bahar; Ersal, Tuba; Gürsoy, Vildan; Yalçın, Cumali; Orhan, Bedrettin; Candar, Ömer; Ali, Rıdvan

doi:10.1002/jca.21995

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining two retrospective studies found no differences in CD34+ cell yields in donors who received OD or BD G-CSF scheduling (51,52). There were no reported associations between G-CSF scheduling and blood CD34 + cell concentration in two retrospective studies (16,52) and one prospective study (49).…”

Section: G-csf Schedulingmentioning

confidence: 95%

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Peck,

Knapp-Wilson,

Burley

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There is a large inter-individual variation in CD34+ cell yield after G-CSF mobilisation and collection from peripheral blood in healthy allogenic haematopoietic stem cell donors. Donor characteristics including gender and age, baseline and precollection blood results, mobilisation factors and collection factors have been associated with CD34+ cell concentration in the blood after G-CSF mobilisation and/or CD34+ cell yield after collection. Since the literature reporting these associations is heterogeneous, we here clarify the determinants of CD34+ cell concentration and yield through a scoping literature review. Materials and Methods: MEDLINE, Embase, PubMed and Stem Cell Evidence were searched for studies published between 2000 and 2023. The inclusion criteria were studies of allogeneic donors undergoing G-CSF mobilisation and peripheral blood stem cell collection (PBSC). Eligible studies assessed an outcome of mobilisation or collection efficacy, indicated by the blood CD34+ cell concentration after 4 or 5 days of G-CSF treatment and/or CD34+ cell yield in the first PBSC collection after mobilisation. Included studies assessed associations between these outcomes and donor factors(such as age, gender, weight, ethnicity), mobilisation factors (G-CSF scheduling or dose), collection factors (venous access, processed blood volume) and laboratory factors (such as blood cell counts at baseline and after mobilisation). Results: The 51 eligible studies evaluated between 23 and 20,884 donors. 43 studies were retrospective, 32 assessed blood CD34+ cell concentration after mobilisation and 37 assessed CD34+ cell yield. In studies that recorded both outcomes, blood CD34+ cell concentration always predicted CD34+ cell yield. The most frequently assessed factor was donor age for which most studies reported that younger donors had a higher blood CD34+ cell concentration and CD34+ cell yield. Non-European ancestry was associated with both higher blood CD34+ cell concentration and yield although this finding was inconsistent. Conclusions: There remains poor consensus about the best predictors of blood CD34+ cell concentration and yield that requires further prospective study, particularly of the role of donor ancestry. The current focus on donor gender as a major predictor may require re-evaluation

show abstract